Healthcare

Medical Care Technologies Inc. (OTC PINK:MDCE) Expands Development of Consumer-Grade AI Pre-Health Screening Tools Focused on Early Detection

MESA, ARIZONA / ACCESS Newswire / December 2, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) announced today that the...

BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from the Italian Ministry of Health Approval to conduct its clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

MILAN, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing...

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Strive Pharmacy Breaks Ground on New 350,000 Sq. Ft. Arizona Headquarters and Compounding Facility, Strengthening Its National Leadership in Patient-Focused Innovation

New Mesa campus deepens Strive's roots in Arizona, expands production capabilities, and accelerates job creation as the company surpasses 700,000...

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia®A novel non-antibiotic approach...

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®-- New Synthetic Process to...

AIML Subsidiary NeuralCloud Enters Pilot with Cornerstone Physiotherapy to Deploy MaxYield(TM) and Insight360(TM) for Elite Athlete Cardiac Performance Testing

Early collaboration supports development of Cornerstone's emerging athlete-performance program and extends NeuralCloud's ECG analytics into sports-science and human performance marketsPilot...

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase...

error: Content is protected !!